TCTMD round table

Gregg W. Stone, MD, FACC, MSCAI is an interventional cardiologist and Director of Academic Affairs for the Mount Sinai Heart Health System and Professor of Medicine (Cardiology) and Professor of Population Health Sciences and Policy at the Icahn School of Medicine at Mount Sinai in New York, NY. Dr. Stone has served as the national or international principal investigator for more than 120 national and international multicenter randomized trials (many of which have led to new device approval or indications in the US), has authored more than 2000 manuscripts and abstracts published in the peer-reviewed literature, and has delivered thousands of invited lectures around the world. With a 2018 H-factor of 152, Dr. Stone was recently listed in Nature Medicine as one of the most prolific authors in science. Dr. Stone's areas of expertise include interventional therapies of acute coronary syndromes, myocardial infarction and cardiogenic shock; drug-eluting stents and bioresorbable scaffolds; left main and complex coronary artery disease intervention; antiplatelet and antithrombotic pharmacotherapies; transcatheter valve repair and replacement; interventional hypertension and heart failure therapies; left atrial appendage closure; intravascular imaging (IVUS, OCT and NIRS); vulnerable plaque diagnosis and treatment; adjunctive interventional devices including atherectomy, distal embolic protection, thrombectomy, covered stents, chronic total occlusion devices, and brachytherapy; saphenous vein graft therapies; contrast nephropathy; clinical trial design; and regulatory issues. Dr. Stone is the director of TCT, the world's largest symposium devoted to interventional cardiology and vascular medicine. Dr. Stone founded the annual National Interventional Cardiology Fellow's Course and Transcatheter Valve Therapies TVT), the Chronic Total Occlusion (CTO) Summit, and co-directs multiple other meetings in the US, China, Russia, Europe, S. Korea and elsewhere.

Consultant Interventional Cardiologist and Revascularisation Group Chair at Royal Brompton Hospital, London. His clinical focus is on use of intravascular imaging in complex PCI , CTO and cardiogenic shock. His clinical research interests focus on optical coherence tomography, calcific coronary disease and percutaneous ventricular support. Dr Hill was global co-chief investigator for the DISRUPT CAD III study and has served as UK principal investigator for multiple interventional trials. He has served as a CTO and complex PCI proctor on a global basis and works closely with OPTIMA to focus on the development of OPTIMAL PCI. He is the founding co-director of the Complete Revascularisation (CoRe) meetings held every year in London.

Ziad Ali is the Director of the DeMatteis Cardiovascular Institute, Director of Investigational Interventional Cardiology, and Director of Cardio-nephrology at St Francis Hospital & Heart Center in New York. He is also Director of the Angiographic Core Laboratory at Cardiovascular Research Foundation and Associate Professor of Medicine at Columbia University Medical Center. His clinical research interests focus on the use of intravascular imaging and physiology technologies such as optical coherence tomography, intravascular ultrasound, and flow wire assessment to optimize coronary interventions, for which he has served as a Global principal investigator on a number of trials. Dr. Ali is also a recognized innovator, playing an integral role in the development of the Resting Full-Cycle Ratio (RFR) and Shockwave intravascular lithotripsy. Clinically Dr. Ali developed pioneering techniques to perform vascular interventions without contrast administration, including IVUS-guided zero-contrast PCI and OCT using saline flush media, protecting patients with advanced kidney disease from acute kidney injury and the need for dialysis.